Peer-reviewed veterinary case report
Ponatinib drug effects on canine mast cell tumor cells in lab tests
By Fisher, C J et al.·Published in Veterinary journal (London, England : 1997)·2021·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of ponatinib in vitro effect in three canine mast cell tumor cell lines expressing FGFR-1, PDGFR-α, and VEGFR-2.
- Species:
- dog
Plain-English summary
A study looked at how well ponatinib, a medication that targets certain cancer-related proteins, works on three types of canine mast cell tumors (MCTs). Researchers found that ponatinib was effective in killing cancer cells in these tumors, showing that it could lead to increased cell death within 12 to 18 hours of treatment. The doses needed for effectiveness were similar to those used in humans, suggesting that ponatinib might be a promising option for treating mast cell tumors in dogs. More research is needed to understand how these proteins relate to the prognosis of the disease.
People also search for: dog mast cell tumor treatment · ponatinib for canine cancer · mast cell tumor symptoms in dogs
Abstract
Ponatinib is a broad-spectrum tyrosine kinase inhibitor that targets numerous receptor tyrosine kinases (RTKs), including but not limited to fibroblast growth factor receptor (FGFR)-1, platelet derived growth factor receptor (PDGFR)-α, and vascular endothelial growth factor receptor (VEGFR)-2. This study evaluated the expression of FGFR-1, PDGFR-α, and VEGFR-2 in three canine mast cell tumor (MCT) cell lines (CM-MC1, VI-MC1, CoMS) and the effects of ponatinib on these MCT cell lines. Quantitative RT-PCR confirmed the expression of FGFR-1, PDGFR-α, and VEGFR-2 in the three MCT cell lines. Ponatinib exhibited dose- and time-dependent cytotoxicity in MCT cell lines via MTT assay. The ICfor 24, 48, and 72 h across the three cell lines ranged from 38.47 nM to 103.3 nM, which is clinically comparable to dose ranges established for humans. Significantly increased apoptosis in each cell line was seen between 12 and 18 h after treatment with ICof ponatinib via Annexin-V and Caspase-3/7 assays. These data suggest that ponatinib could be a possible therapeutic agent for canine MCTs. Further studies are needed to investigate the prognostic value of FGFR-1, PDGFR-α, and VEGFR-2 in canine MCTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33593493/